Novotech Strengthens Presence in Japan with Opening of Tokyo Office
核心洞察
Novotech (搜索), a global full-service biotech CRO, has opened a new office in Tokyo to strengthen its established presence in Japan.
The Tokyo office will serve as a strategic hub, enhancing local expertise and collaboration with clients, partners, and research institutions across the region.
The investment supports Japanese biopharma companies advancing programs regionally and across key international markets, including Asia-Pacific, the United States, and Europe.
Novotech (搜索), a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech's existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets.
The Tokyo office will serve as a strategic hub for Novotech (搜索)'s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, FDA-aligned protocol development, US-based scientific expertise, and international partnering opportunities.
Strategic Rationale for the Tokyo Expansion
Japan is one of the world's largest and most advanced pharmaceutical markets, supported by a sophisticated research base and a rapidly evolving biotech sector. As more Japanese biopharma companies look to expand beyond domestic development and bring novel therapies to global markets, Novotech (搜索)'s expanded presence in Tokyo strengthens its ability to support cross-border clinical trials and connect sponsors across Asia-Pacific, the United States, and Europe.
Novotech (搜索)'s global operating model is particularly well aligned to the needs of emerging and growth-stage biopharma companies, providing flexible, high-quality clinical development support without the complexity of managing multiple regional providers. The company brings deep experience across therapeutic areas including oncology, rare diseases, central nervous system disorders, infectious diseases, immunology, and advanced therapies, supported by strong regulatory, scientific, and operational expertise across major clinical trial markets.
Leadership Perspective
Takeshi Mori, Country Head, Japan, commented: "The opening of our Tokyo office is an important milestone for Novotech (搜索). Japan is a critical market for global clinical development, and this investment reflects our long-term commitment to building strong local capabilities while delivering high-quality services to our clients."
The office is located at 27F Shinjuku i-Land Tower, 6-5-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan 163-1327.
Global Footprint and Capabilities
The opening of the Tokyo office builds on Novotech (搜索)'s established presence in Japan and reflects its broader strategy to strengthen its global footprint and position itself as a leading CRO partner for biotech companies worldwide. Novotech is a globally recognized full-service clinical research organization and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 7,000+ trial sites, Novotech (搜索) provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies.